Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma

Not yet recruitingOBSERVATIONAL

Enrollment

400

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

December 30, 2025

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)Double Expressor Lymphoma

All Listed Sponsors

lead

Ruijin Hospital

OTHER